Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical use of wedelolactone and its derivative

A technology of wedelolide and its derivatives, which is applied in the field of pharmaceutical use of wedelide and its derivatives, can solve the problems of unreported application, and achieve the effect of high selectivity, long history and positive curative effect

Inactive Publication Date: 2008-09-10
SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
View PDF1 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the application in the preparation of drugs for the treatment of T cell-mediated immune damage diseases (chronic hepatitis or autoimmune hepatitis)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical use of wedelolactone and its derivative
  • Pharmaceutical use of wedelolactone and its derivative
  • Pharmaceutical use of wedelolactone and its derivative

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0037] The present invention is described in detail below through examples.

[0038] 1. Raw materials

[0039] Kunming mice, 20g, clean grade. BALB / c mice aged 6-8 weeks, clean grade. Melanoma cell B16, mouse fibroblast L929.

[0040] Bifendate dropping pills; concanavalin A (ConA); RPMI 1640; tetramethylazoazole MTT (Fluka); ALT kit; lymphocyte separation fluid (density 1.077), CD 3 - PI antibody; CD 4 - FITC antibody; CD 8 -Cy 5 Antibody; 96-well culture plate; silica gel (100-200 mesh) for chromatographic column, RPMI 1640 nutrient solution; DMSO (AR); tritium-deoxythymidine ( 3 H-TdR); concanavalin A (ConA); 96-well culture plate; medicinal material Eclipta chinensis; other reagents were domestic analytical grade.

[0041] 2. Test steps

[0042] (1) Drug preparation

[0043] The medicinal material Eclipta chinensis was extracted three times with 80% ethanol under reflux, each time for 2 hours, concentrated and dried under reduced pressure to prepare the extract, t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
densityaaaaaaaaaa
Login to View More

Abstract

The invention relates to medical applications of wedelolactone and derivatives thereof, in particular to the applications in preparing medicines for treating T-cell mediated immunologic injury diseases (chronic hepatitis or autoimmune hepatitis). Traditional Chinese Medicine eclipta has a function of liver protection; wedelolactone is prepared after the active ingredient of eclipta is traced and separated, so the pharmaceutical function is proved to be produced by wedelolactone; the structure of wedelolactone is determined through the spectrum properties and physicochemical properties. Wedelolactone is provided with biological activities: high selective inhibition to ConA stimulated T lymphocyte proliferation, no inhibition to normal peripheral blood lymphocyte (NPBL), and no cytotoxicity; wedelolactone is the active ingredient of Traditional Chinese Medicine with liver protection function; the method for preparing a novel medicine from the active ingredient of eclipta, wedelolactone, has the advantages of discarding the dross and selecting the essential, clear medicinal ingredients, definite function, safety and effectiveness, controllable quality, reducing the adverse drug reaction, and can be suitable for mass production.

Description

【Technical field】 [0001] The invention relates to the medicinal use of wedelolide and its derivatives, in particular to its application in the preparation of medicines for treating T cell-mediated immune injury diseases (chronic hepatitis or autoimmune hepatitis). 【Background technique】 [0002] The incidence of T cell-mediated immune damage diseases is on the rise. Viral hepatitis is a self-limiting self-healing disease. The course of the disease includes three steps: infection-clearance-self-healing. Therefore, acute viral hepatitis only needs to be given appropriate symptomatic treatment, and the immune response can help clear the virus. However, when the course of the disease repeatedly stays in the process of infection-clearance, and the course of the disease is extended to several years or even decades, it is clinically chronic hepatitis. Viral infection is only the causative factor, but not the main mechanism. Hepatitis B virus cannot directly cause liver cell disea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/366A61P1/16
Inventor 徐汝明陆阳李宁丽邓克敏徐德锋崔永耀
Owner SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products